Healthpeak Properties (DOC) Stock May Be 42% Undervalued Following A $2.1b Joint Venture

Healthpeak Properties has returned 37.0% year to date, yet its valuation checks send mixed signals, with a Discounted Cash Flow (DCF) estimate pointing to material upside while market multiples suggest the stock screens as expensive.

• The 37.0% year to date gain may already reflect a lot of optimism about Healthpeak Properties' outlook, so fresh buyers need to think carefully about the margin of safety at current levels.
• The recent US$2.1b joint venture with Brookfield Asset Management can support long term cash generation from outpatient medical buildings, but concentration in a specific healthcare segment may add risk if tenant demand or reimbursement trends soften.
• With the company scoring just 2 of 6 on broader valuation checks, Healthpeak Properties does not screen as a straightforward bargain even though the intrinsic value estimate suggests it may be trading at a 41.9% discount.

The issue now is whether investors should trust the intrinsic value estimate that points to undervaluation or the market multiples that imply Healthpeak Properties is already priced for a lot of good news.

Find out why Healthpeak Properties' 24.6% return over the last year is lagging behind its peers.

Is Healthpeak Properties Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) approach here values Healthpeak Properties using adjusted funds from operations rather than reported earnings. On this model, the company generated about $1.29b in free cash flow over the last twelve months, and the projections assume cash flows that grow gradually rather than sharply. On those inputs, the intrinsic value is estimated at about $38 per share.

Compared with the current share price, that estimate implies Healthpeak Properties trades at roughly a 41.9% discount, so the DCF suggests the stock appears undervalued based on its cash generation. Because the recent US$2.1b joint venture with Brookfield keeps Healthpeak managing the outpatient portfolio and retaining a majority stake, the market may still be underpricing the associated fee and ownership cash flows.

On this DCF view, Healthpeak Properties stock screens as undervalued relative to the cash flows implied by its current price.

Our Discounted Cash Flow (DCF) analysis suggests Healthpeak Properties is undervalued by 41.9%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Healthpeak Properties.

Is Healthpeak Properties Getting Expensive on Earnings?

P/E is a useful cross check for Healthpeak Properties because earnings are a key anchor for how REITs are typically valued in the public market. On this measure, Healthpeak Properties trades at about 69.0x earnings, which sits well above the Health Care REITs industry average of roughly 19.9x and also above the peer group average of 47.1x.

The tailored fair P/E ratio for Healthpeak Properties is estimated at about 20.8x, and the large gap to the current 69.0x suggests the stock screens as expensive on this framework. Because the model is heavily penalising the company’s risk profile and earnings quality, that fair multiple is better viewed as a warning flag about how rich the current valuation looks rather than a precise target.

On the P/E multiple, Healthpeak Properties stock currently appears overvalued compared with both its industry and what the company’s fundamentals would typically support.

See what the numbers say about this price — find out in our valuation breakdown.

The Healthpeak Properties Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation split for Healthpeak Properties leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than its current price. Each narrative links a specific fair value to a clear story about Healthpeak Properties' potential catalysts and risks, so you can track over time which version of events seems closest to reality on the Community page.

The community is split on Healthpeak Properties, with one group leaning into an upside story and another warning that expectations already look stretched.

Bull case: 18% undervalued

"Healthpeak's unique, high-concentration positions in premier high-growth Sunbelt and innovation markets, deep health system relationships, and a war chest for opportunistic acquisitions in a distressed competitive landscape..."

Read the full Bull Case to see why Healthpeak Properties could be undervalued

Bear case: roughly fairly valued

"Concentrated exposure to capital, regulatory, and tenant risks threatens Healthpeak's revenue stability, margin growth, and flexibility for investment or dividend expansion..."

Read the full Bear Case to see why Healthpeak Properties could be overvalued

Do you think there's more to the story for Healthpeak Properties? Head over to our Community to see what others are saying!

The Bottom Line

Healthpeak Properties sits in a tension between a Discounted Cash Flow (DCF) view that flags meaningful upside and market multiples that say the stock already prices in rich expectations. The split largely comes from how differently cash flows and earnings are being treated, with the intrinsic value leaning on long term cash generation and the P/E view heavily penalising risk and current earnings power. Given the weak broader valuation score, it is hard to lean only on the DCF signal. The crux from here is whether Healthpeak’s outpatient focused cash flows prove resilient enough to justify today’s high multiple, rather than the discount turning into a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com